A Phase 1 Study to Assess the Safety, Radiation Dosimetry and Biodistribution, and Basic Pharmacokinetics of [18F]GEH121224 and Determine the Optimal Timing of Imaging in Patients With Locally Advanced or Metastatic Breast Cancer.
Latest Information Update: 10 Feb 2025
At a glance
- Drugs Fluorine 18 GEH121224 (Primary)
- Indications Breast cancer; HER2 positive breast cancer
- Focus Adverse reactions; Diagnostic use
Most Recent Events
- 04 Feb 2025 Planned End Date changed from 1 Dec 2025 to 1 Dec 2026.
- 04 Feb 2025 Planned primary completion date changed from 1 Dec 2025 to 1 Dec 2026.
- 04 Feb 2025 Planned initiation date changed from 1 Jan 2025 to 1 Feb 2026.